Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

Former CNET editor Dong Ngo has been involved with technology since 2000, starting with testing gadgets and writing code for CNET Labs' benchmarks. He managed CNET's San Francisco Labs, reviews 3D ...

Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows ...

Cel-Sci is struggling to commercialize its Multikine cancer therapy; it recently closed on a small but expensive financing. The company has completed its initial end of phase 3 meeting with the FDA; ...

Investigators at Memorial Sloan Kettering Cancer Center (MSK) have published results from a clinical trial that found people with recurrent multiple myeloma may benefit from receiving chimeric antigen ...

Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook Almost a quarter century ago today, the Xbox debuted one of its most distinct launch titles — and ...

Beam Therapeutics advances base-editing pipeline with risto-cel studies and FDA designations, but no approved products and rising competition loom.

Crypto lending platform Celsius Network has an approximately $1.2 billion gap in its balance sheet, with most liabilities owed to its users. In addition, the firm has filed for bankruptcy protection, ...

This new Registration Study targets the population of previously untreated resectable stage 3 and 4 head and neck cancer patients who had no lymph node involvement and low PD-L1 tumor expression.

The CEL Core program enhances the talents and abilities of practicing entrepreneurs. The mentor-driven program empowers entrepreneurs to overcome business challenges, create new opportunities and ...